Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Topoisomerase
    (11)
  • Apoptosis
    (4)
  • ADC Cytotoxin
    (3)
  • Antibody-Drug Conjugates (ADCs)
    (2)
  • Autophagy
    (2)
  • HIV Protease
    (2)
  • Mitophagy
    (2)
  • NF-κB
    (2)
  • AMPK
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

human topoisomerase i

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    17
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    2
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    6
    TargetMol | Natural_Products
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Disease Modeling
    1
    TargetMol | Disease_Modeling_Products
Trastuzumab deruxtecan
VRN-101099, T-DXd, DS-8201a, DS 8201
T366461826843-81-5
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
  • $521
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38
T9901A-1017
Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) composed of the human anti-CCL2 (chemokine ligand 2) antibody Carlumab, connected via the Mc-VC-PAB linker to the topoisomerase I inhibitor SN38. The toxic component and linker of the ADC is Mc-VC-PAB-SN38. This ADC is employed in cancer research studies.
  • Inquiry Price
Size
QTY